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TO THE EDITOR
The conventional pharmacokinetic
profiles of drugs are described mainly
through the plotting of drug–plasma
concentration against time. This is
clearly appropriate for most of the
orally administered drugs that undergo
systemic absorption before distribution
to the site of action. However some
drugs, such as local anesthetics, anti-
fungal agents, and topical cortico-
steroids, are designed to target the local
tissue where they are applied and, as
such, have limited systemic absorption.
For these drugs, the pharmacokinetic
measurements in the local tissue are of
more interest than the systemic mea-
surement. A number of in vitro and
in vivo techniques are available for
direct measurement of pharmacokinetic
and clinically relevant information
about drug concentration in the target
tissue and skin. Animal skin and
excised human skin are available to
use in in vitro experiments such as those
using Franz-type diffusion cells (Franz,
1976). However, the data obtained from
excised skin may not translate directly
to the in vivo situation. There are a
few in vivo techniques that enable
acquisition of drug concentration infor-
mation in the skin and a pharmaco-
kinetic profile. These techniques include
dermal microdialysis (DMD; Anderson
et al., 1992; Hegemann et al., 1995;
Benfeldt, 1999), tape stripping or
dermatopharmacokinetics (DPK; Pershing
et al., 2003), the skin blister fluid method
(Nowak and Klimowicz, 1990), magnetic
resonance imaging (Jynge et al., 1990),
and biopsy followed by tissue homo-
genization (Roos and Brorson, 1990).
Of these techniques, microdialysis
and tape stripping are the most widely
used for the pharmacokinetic assess-
ment of skin because these methods
are easier to perform, produce reliable
results, and are less invasive.
In this study, which was approved
by the United Kingdom’s Central Office
for Research Ethics Committees, we
evaluated the DMD and tape-stripping
(DPK) techniques in the pharmaco-
kinetic assessment of topical drugs
and compared the results with those of
conventional systemic drug measure-
ments in blood. The study was con-
ducted according to the Declaration of
Helsinki Principles. It was an open-
label study, with two visits and a
1-week washout period. DMD and
blood sampling were performed in
parallel on one occasion and DPK was
performed on another occasion. The
study involved 12 healthy subjects,
and participants gave their written
informed consent. On the microdialysis
study day, a CMA 60 microdialysis
catheter was used together with a
CMA 106 microdialysis pump supplied
by CMA Microdialysis, Solna, Sweden.
The adhesive tape used on the DPK
study day was TESA 4204 PV5, sup-
plied by TESA, Milton Keyness, UK.
EMLA cream (AstraZeneca, Bristol, UK)
containing 2.5% lidocaine and 2.5%
prilocaine was used as a study drug. In
the DMD experiment, the probe (3 cm
long) was inserted under the treatment
area (subcutaneous tissue) and the
sampling was carried out every 20 min-
utes until 4 hours after the dose. The
treatment was 1 g EMLA cream applied
to a 10-cm2 circular area of the skin.
A 20-gauge cannula was cannulated on
the contralateral arm for the venous
sampling. Venous samples were col-
lected at 0, 20, and 40 minutes and 1,
1.5, 2, 2.5, 3, 3.5, and 4 hours after the
dose. The residual drug was removed
from the treated area 1 hour after
treatment application.
On another occasion, the tape strip-
ping was carried out on the skin
surface. Tape stripping was performed
at 0, 15, 30, and 45 min and 1 hour
after the dose for the uptake phase
(sites 1, 2, 3, 4, and 5) and 1.5, 2, 3, and
4 hours after the dose for the elimina-
tion phase (sites 6, 7, 8, and 9). The
treatments were 1 g EMLA cream
applied to 10 demarcated rectangular
areas of the skin (6 cm2). Before collec-
tion of stratum corneum from the
treated skin site, the residual product
was removed from the skin surface
using a metal spatula and three dry
cotton-wool tips used independently.
Site 1 served as a control (0 hour
sampling). The residual product was
removed at 15, 30, and 45 min from
sites 2, 3, and 4. For sites 5–9, the
residual product was removed at
1 hour. After product removal from
the skin, the first adhesive tape was
applied and briskly rubbed with blunt-
ended forceps to collect the stratum
corneum. The tape was removed using
the forceps. As a precaution, the first
adhesive tape was discarded to avoid
potential contamination from any resi-
dual product not removed with the dry
cotton wool (Weigmann et al., 1999).
The remaining nine adhesive tapes
were applied sequentially using the
procedure described above and kept
in a polypropylene tube until further
analysis. The lidocaine concentration
from plasma and DMD samples was
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Abbreviations: DMD, dermal microdialysis; DPK, dermatopharmacokinetic
analyzed using the validated liquid
chromatography–mass spectrometry/mass
spectrometry method (Chik et al., 2006),
and the lidocaine content in the tape
samples was analyzed using capillary
electrophoresis with UV detection (Chik
et al., 2007).
Table 1 summarizes the pharmaco-
kinetic parameters derived for lidocaine,
and Figure 1 shows the lidocaine con-
centration-versus-time plot for all the
three methods studied. There was a
higher area under the curve and Cmax
(maximum plasma concentration) with
DPK as compared with DMD and
plasma. The median time to the highest
plasma lidocaine concentration, tmax,
was significantly shorter in the stratum
corneum as compared with plasma,
with values of 1.00 versus 3.25 hours
(Po0.001). The higher lidocaine profile
yielded by the DPK and DMD methods
is advantageous for pharmacokinetic
measurement when compared with
the low lidocaine profiles obtained
from systemic measurement. The results
showed that lidocaine was rapidly
detected in the stratum corneum soon
after treatment application. At 1 hour
after application of EMLA, its levels in
the stratum corneum were higher than
those in the subcutaneous layer of
the skin or in blood. The decrease in
the amount of lidocaine after 1 hour in
the DPK samples can be explained by
the increased of lidocaine concentration
in the dialysate. This remained elevated
even at the 4-hour sampling time. In
a comparison of the DPK and DMD
methods, good reproducibility and less
variability were shown by the DPK
method. The greater variability in the
DMD data than with plasma and DPK
may be a reflection of the depth of the
probe implantation, as the same subjects
were used for all three techniques.
Moreover, the validation of within- and
between-probe recovery showed a low
variability in the three probes studied.
Therefore, between- and within-probe
variability was minimal and did not
contribute significantly to the variability
observed. However, more research and
data regarding the reliability of DMD
and DPK are necessary to determine
the ideal methods for pharmacokinetic
assessment of topical drugs.
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Figure 1. Plot of mean lidocaine concentration versus time (h) in tape, dialysate, and plasma samples
on log scales.
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TO THE EDITOR
Alopecia areata (AA) is a chronically
relapsing skin disorder characterized
by a sudden loss of hair. Because the
perception of patients may differ
significantly from those of their
health-care providers, quality of life
(Qol) appears to be a more relevant
criterion to assess the severity of this
disease than clinical evaluation such as
AA extension. To our knowledge, only
one Turkish study investigated the
impact of AA on Qol using short form
36 (SF36), indicating lower Qol levels
compared with sex-matched indivi-
duals (Gulec et al., 2004). In this study,
Qol was assessed using a generic
instrument. Because only three dimen-
sions were affected and results may be
linked to the specific culture, a con-
firmation was needed. We used an
approach combining generic and spe-
cific measures to assess the impact of
AA on French patients’ Qol, to compare
Qol levels with those observed in the
general population and in other derma-
tological conditions, and finally to
determine the impact of clinical char-
acteristics and sociodemographic fac-
tors on Qol.
Subjects were aged over 16 years,
presenting with a minimum of 8 weeks
AA history, having given informed
consent to participate, and having the
French language as their native lan-
guage. Sociodemographic data and
characteristics of the disease (duration
and course, treatments in the recent
period, affected surfaces on the scalp
and other areas involved) were re-
corded. The severity of each AA was
reported using visual analogical scales
(0–10) by reference to (i) all the AA
cases seen in daily practice; (ii) all
cases of all skin disorders. Three self-
administered questionnaires were used
to assess Qol: the generic and world-
wide-used SF36 (Leplege et al., 1998,
2001; Coste, 2001), and two ‘‘chronic
skin disorders’’-specific Qol instru-
ments with French validated available
versions, the VQ-Dermato (Grob
et al., 1999, 2009) and the Skindex
(Chren et al., 1996, 1997; Leplege
et al., 2003). To better figure out the
level of QoL in AA, we compared
AA scores with those available in
literature related to the French popula-
tion: (1) rare dermatological diseases
including hidradenitis suppurativa
(Wolkenstein et al., 2007) and neurofi-
bromatosis type 1 (Wolkenstein et al.,
2001); (2) chronic/frequent dermatolo-
gical diseases including psoriasis,
chronic idiopathic urticaria, and atopic
dermatitis (Grob et al., 2005); (3)
general population: French age- and
sex-matched controls (Leplege et al.,
2001). This study was conducted in
adherence to the Helsinki guidelines.
Institutional approval was not required
for experiments. After having given
their inform consent, 60 patients were
included (39 women and 21 men);
their mean age was 40.1 years (SD
15.2) and median AA duration was
6 years (2 months to 60 years). Course
of the disease was stable in 25 subjects
and unstable in 35. The median of
the scalp surface involved was 77%.
The median of severity score was 6.5
(range 4.0–9.0) by reference to the AA
patients and 3.5 (range 2.0–6.0) by
reference to the patients presenting
any skin disorder.
Mental health and vitality were the
most altered SF36 dimensions, whereas
physical functioning, role physical and
body pain were the least ones. Regard-
ing VQ-Dermato, daily life, leisure
activity, and physical discomfort were
the least altered dimensions. For Skin-
dex, emotions dimension was the most
affected and symptoms the least one.
Compared with the general population
and with patients suffering from other
dermatological conditions (Table 1), AA
patients presented significantly altered
Qol for almost all the SF36 dimensions.
For VQ-Dermato, AA patients reported
(i) significantly better (mood state,
leisure activity, daily life, and physical
discomfort) or worse scores (self-per-
ception) than psoriasis, chronic idio-
pathic urticaria, and atopic dermatitis
patients; (ii) being less bothered to
treatment-induced restrictions than
psoriasis, but more than chronic idio-Abbreviations: AA, alopecia areata; Qol, quality of life; SF36, short form 36
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